ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Sells Dermik Unit To Valeant For $425 Million

PARIS -(Dow Jones)- French pharmaceutical giant Sanofi SA (SAN.FR) said Monday it sold Dermik, its dermatology unit, to Canada-based Valeant Pharmaceuticals International Inc. (VRX) for $425 million in cash. The transaction involves Dermik assets, comprising an aesthetic and therapeutic dermatology business in the U.S. and Canada and an aesthetic dermatology business in other parts of the world, which had sales of $206 million in 2010, Sanofi said. Dermik has a significant presence in the medical dermatology market in the U.S. and Canada, with a strong field force and well-known brands, which include BenzaClin, Carac and Sculptra. Sanofi decided to sell Dermik to focus on its "growth platforms" and "innovation." The French company recently bought U.S. biotech firm Genzyme for $20 billion and a string of smaller firms prior to the Genzyme takeover. The transaction will still have to be cleared by certain antitrust authorities and meet other customary conditions. -By Inti Landauro, Dow Jones Newswires; +33 1 4017 1740; inti.landauro@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/05/201617:06:17Amended Statement of Beneficial Ownership (sc 13d/a)
02/04/201612:57:00Martin Shkreli Takes the Fifth Before Congress--3rd Update
02/04/201611:23:00Martin Shkreli Takes the Fifth Before Congress--2nd Update
02/04/201611:13:00Martin Shkreli Takes the Fifth Before Congress--Update
02/04/201611:00:00Martin Shkreli Takes the Fifth Before Congress
02/04/201610:50:00Martin Shkreli Takes the Fifth Before Congress
02/03/201618:49:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:30:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:19:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/02/201620:12:00Correction to Companies Boosted Drug Prices To Fuel Preset Profits
02/02/201617:30:17Current Report Filing (8-k)
02/02/201616:20:00Valeant, Turing Boosted Drug Prices To Fuel Preset Profits
01/28/201616:12:26Statement of Changes in Beneficial Ownership (4)
01/25/201608:48:00Valeant's Pearson: 'On the Road to Recovery' -- 2nd Update
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson
01/20/201618:30:00Valeant Interim CEO to Testify Before Congress
01/20/201618:19:00Valeant Pharmaceutical Interim CEO to Testify Before Congress...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad